

KX2-391 (dihydrochloride)

Catalog No: tcsc0455



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

1038395-65-1

Formula:

$C_{26}H_{31}Cl_2N_3O_3$

Pathway:

Protein Tyrosine Kinase/RTK;Cell Cycle/DNA Damage;Cytoskeleton

Target:

Src;Microtubule/Tubulin;Microtubule/Tubulin

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Observed Molecular Weight:

504.45

Product Description


KX2-391 (dihydrochloride) is an inhibitor of **Src** that targets the peptide substrate site of Src, with **GI₅₀** of 9-60 nM in cancer cell

lines.

IC50 & Target: GI50: 9 nM (Src HuH7), 13 nM (Src PLC/PRF/5), 26 nM (Src Hep3B), 60 nM (Src HepG2)

In Vitro: KX2-391 is a Src inhibitor that is directed to the Src substrate pocket. KX2-391 shows steep dose-response curves against Huh7 (GI_{50} =9 nM), PLC/PRF/5 (GI_{50} =13 nM), Hep3B (GI_{50} =26 nM), and HepG2 (GI_{50} =60 nM), four hepatic cell cancer (HCC) cell lines [1]. KX2-391 is found to inhibit certain leukemia cells that are resistant to current commercially available drugs, such as those derived from chronic leukemia cells with the T3151 mutation. KX2-391 is evaluated in engineered Src driven cell growth assays in NIH3T3/c-Src527F and SYF/c-Src527F cells and exhibits GI_{50} with 23 nM and 39 nM, respectively [2].

In Vivo: Orally administered KX2-391 is shown to inhibit primary tumor growth and to suppress metastasis, in pre-clinical animal models of cancer [2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!